<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
<title>Pädiatrische Hämatologie und Onkologie</title>
<link href="https://hdl.handle.net/20.500.11811/816" rel="alternate"/>
<subtitle/>
<id>https://hdl.handle.net/20.500.11811/816</id>
<updated>2026-05-03T08:04:37Z</updated>
<dc:date>2026-05-03T08:04:37Z</dc:date>
<entry>
<title>Rapid protection against viral infections by chemokine-accelerated post-exposure vaccination</title>
<link href="https://hdl.handle.net/20.500.11811/13031" rel="alternate"/>
<author>
<name>Heine, Annkristin</name>
</author>
<author>
<name>Lemmermann, Niels A. W.</name>
</author>
<author>
<name>Flores, Chrystel</name>
</author>
<author>
<name>Becker-Gotot, Janine</name>
</author>
<author>
<name>Garbi, Natalio</name>
</author>
<author>
<name>Brossart, Peter</name>
</author>
<author>
<name>Kurts, Christian</name>
</author>
<id>https://hdl.handle.net/20.500.11811/13031</id>
<updated>2025-04-30T11:46:56Z</updated>
<published>2024-01-29T00:00:00Z</published>
<summary type="text">Rapid protection against viral infections by chemokine-accelerated post-exposure vaccination
Heine, Annkristin; Lemmermann, Niels A. W.; Flores, Chrystel; Becker-Gotot, Janine; Garbi, Natalio; Brossart, Peter; Kurts, Christian
&lt;strong&gt;Introduction:&lt;/strong&gt; Prophylactic vaccines generate strong and durable immunity to avoid future infections, whereas post-exposure vaccinations are intended to establish rapid protection against already ongoing infections. Antiviral cytotoxic CD8 + T cells (CTL) are activated by dendritic cells (DCs), which themselves must be activated by adjuvants to express costimulatory molecules and so-called signal 0-chemokines that attract naive CTL to the DCs.&lt;br /&gt; &lt;strong&gt;Hypothesis:&lt;/strong&gt; Here we asked whether a vaccination protocol that combines two adjuvants, a toll-like receptor ligand (TLR) and a natural killer T cell activator, to induce two signal 0 chemokines, synergistically accelerates CTL activation.&lt;br /&gt; &lt;strong&gt;Methods:&lt;/strong&gt; We used a well-characterized vaccination model based on the model antigen ovalbumin, the TLR9 ligand CpG and the NKT cell ligand &lt;em&gt;&amp;alpha;&lt;/em&gt;-galactosylceramide to induce signal 0-chemokines. Exploiting this vaccination model, we studied detailed T cell kinetics and T cell profiling in different in vivo mouse models of viral infection.&lt;br /&gt; &lt;strong&gt;Results:&lt;/strong&gt; We found that CTL induced by both adjuvants obtained a head-start that allowed them to functionally differentiate further and generate higher numbers of protective CTL 1-2 days earlier. Such signal 0-optimized post-exposure vaccination hastened clearance of ex perimental adeno virus and cytomegalovirus infections.&lt;br /&gt; &lt;strong&gt;Conclusion:&lt;/strong&gt; Our findings show that signal 0 chemokine-inducing adjuvant combinations gain time in the race against rapidly replicating microbes, which may be especially useful in post-exposure vaccination settings during viral epi/pandemics.
</summary>
<dc:date>2024-01-29T00:00:00Z</dc:date>
</entry>
</feed>
